Skip to main content
. 2017 Jul 17;8:441. doi: 10.3389/fphar.2017.00441

Figure 4.

Figure 4

AAVrh.10-S671A mutant vectors resist neutralization by circulating antibodies in vivo. IVIG from Intratect®, Biotest, Dreieich, Germany (2mg/animal) was injected intra-peritoneally into C57BL/6 mice 24 h prior to administration of the WT-AAVrh.10 and the AAVrh.10-S671A vectors. C57BL/6 mice that were not administered with IVIG were also injected with these vectors (control group). Panel (A) Bio-luminescence imaging of mice administered with WT-AAVrh.10 or its mutant in the presence or absence of IVIG at 5, 14, and 30 days post-vector transduction. Panel (C) represents the experiment performed under the same conditions but with a different IVIG source (IVIGlob® EX, VHB Life Sciences Ltd, Mumbai, India). Panel (B,D) represent quantified data of the luciferase expression obtained from (A,C), respectively. *p < 0.05, in comparison to control group. Representative images are shown in the figure.